Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCBX.L Regulatory News (CBX)

  • There is currently no data for CBX

Issue of Equity

14 Jul 2010 07:00

14 July 2010 Cubus Lux plc ("Cubus Lux" or the "Company") Issue of Equity

The Company is pleased to announce that it has raised £325,000 through the issue of 2,321,429 new ordinary shares of 10p each (the "Placing Shares") at 14p per share. The funds raised will be used to finance certain project costs and short term working capital commitments.

The Placing Shares represent 10.8 per cent. of the Company's enlarged share capital and application has been made for their admission to trading on AIM. It is expected that dealings will commence at 8.00 a.m. on 19 July 2010.

The Placing Shares have been issued, in part, to three directors of the Company; Gerhard Huber, Christian Kaiser and Steve McCann. Following the issue of the Placing Shares the interests of these directors is as follows:

Director Placing Shares Current Percentage Options Held

issued Shareholding Shareholding Gerhard Huber 714,286 3,930,948 18.2% 2,200,000 Christian Kaiser 357,143 2,608,748 12.1% 600,000 Steve McCann 714,286 744,286 3.4% 1,130,000

The issue of the Placing Shares to Mr Huber, Mr Kaiser and Mr McCann is deemed a related party transaction under the AIM Rules for Companies. The independent directors, having consulted with Astaire Securities plc, as the Company's nominated adviser, consider that the terms of the transaction are fair and reasonable in so far as the Company's shareholders are concerned.

Following this issue of shares, the Group will have an issued share capital of 21,582,551 ordinary shares of 10p each. As the Group does not hold any ordinary shares in Treasury its total number of voting rights equals its capital. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FSA's Disclosure and Transparency Rules.

For further information about the Company please see www.cubuslux.com orcontact:Cubus Lux plc Steve McCann +44 (0) 7787 183 184 Astaire Securities Antony Legge / Luke Cairns +44 (0) 20 7448 4400plc (Nomad)

Hybridan LLP (Broker) Claire Louise Noyce / Stephen +44 (0) 20 7947 4350

Austin City Road Pam Spooner +44 (0) 20 7248 8010

Communications

vendor
Date   Source Headline
28th Mar 20224:35 pmRNSPrice Monitoring Extension
28th Mar 202211:00 amRNSPrice Monitoring Extension
22nd Mar 20227:00 amRNSDirectorate change
14th Mar 20224:41 pmRNSSecond Price Monitoring Extn
14th Mar 20224:36 pmRNSPrice Monitoring Extension
14th Mar 20222:05 pmRNSSecond Price Monitoring Extn
14th Mar 20222:00 pmRNSPrice Monitoring Extension
14th Mar 20227:00 amRNSLaunch of outdoor marketing campaign
8th Mar 202211:03 amRNSShare purchase by CEO
7th Mar 202211:05 amRNSSecond Price Monitoring Extn
7th Mar 202211:00 amRNSPrice Monitoring Extension
4th Mar 20224:41 pmRNSSecond Price Monitoring Extn
4th Mar 20224:36 pmRNSPrice Monitoring Extension
2nd Mar 20227:00 amRNSExercise of Warrants
1st Mar 20227:00 amRNSLaunch of Rejuvenating Cannabinoid Face Serum
23rd Feb 20224:41 pmRNSSecond Price Monitoring Extn
23rd Feb 20224:36 pmRNSPrice Monitoring Extension
23rd Feb 20222:06 pmRNSSecond Price Monitoring Extn
23rd Feb 20222:01 pmRNSPrice Monitoring Extension
21st Feb 202211:05 amRNSSecond Price Monitoring Extn
21st Feb 202211:00 amRNSPrice Monitoring Extension
21st Feb 20229:05 amRNSSecond Price Monitoring Extn
21st Feb 20229:00 amRNSPrice Monitoring Extension
21st Feb 20227:00 amRNSStrategy and trading update
2nd Feb 20227:00 amRNSWhite paper on cannabinoids and skin aging
7th Jan 20221:00 pmRNSResults of Annual General Meeting
15th Dec 20217:00 amRNSAnnual General Meeting update
8th Dec 20217:00 amRNSGrant of Options to CEO
6th Dec 20211:57 pmRNSPosting of Annual Report and Notice of AGM
6th Dec 20217:00 amRNSAppointment of new CEO
3rd Dec 20217:00 amRNSAnnual results
1st Dec 20217:00 amRNSLaunch of inaugural products & ecommerce platform
11th Nov 20217:00 amRNSAdvertising and PR agencies appointed
8th Nov 20212:05 pmRNSSecond Price Monitoring Extn
8th Nov 20212:00 pmRNSPrice Monitoring Extension
8th Nov 202111:05 amRNSSecond Price Monitoring Extn
8th Nov 202111:00 amRNSPrice Monitoring Extension
1st Nov 20217:00 amRNSGrant of Share Options and update on warrants
4th Oct 20219:06 amRNSSecond Price Monitoring Extn
4th Oct 20219:00 amRNSPrice Monitoring Extension
4th Oct 20217:00 amRNSDirector dealings & TR1 notification
16th Aug 20217:00 amRNSSupply agreement signed with Chanelle McCoy Health
2nd Aug 20217:00 amRNSShare disposal by significant shareholder
28th Jul 20212:06 pmRNSSecond Price Monitoring Extn
28th Jul 20212:00 pmRNSPrice Monitoring Extension
10th Jun 20217:00 amRNSSupply agreement signed with Willow Biosciences
25th May 20217:00 amRNSCellular Goods Interim Results
6th May 20217:00 amRNSGrant of Warrants and Extension of Exercise Period
20th Apr 20212:00 pmRNSPrice Monitoring Extension
12th Apr 20217:00 amRNSCellular Goods boosts team with five appointments

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.